← All Compounds
Mechanism Synthetic fragment of Thymosin Beta-4. Upregulates actin, promotes cell migration and differentiation, reduces inflammation, and supports tissue repair. Half-Life Estimated 2-3 hours Route subcutaneous Frequency 2x/week (loading), 1x/week (maintenance)
FDA Category Research peptide (removed from FDA Category 2) Reclassification removed-from-cat2 Date Restricted 2023-09-29 Announced Return 2026-02-27
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
TB-500
Removed from Cat 2
Growth & Recovery · Research peptide (multiple suppliers)
Synthetic fragment of Thymosin Beta-4 researched for tissue repair, cell migration, and anti-inflammatory effects. Not FDA-approved for any indication.
About
Clinical Dosing
2-5 mg2x/week (loading), 1x/week (maintenance)
Removed from Category 2 by FDA (April 15, 2026). Will be evaluated by PCAC beginning July 2026. Not yet Category 1 — awaiting formal PCAC review.
Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Loading/Maintenance Protocol
| Dose | Duration | Draw (2 mg vial in 2mL) | Notes |
|---|---|---|---|
| 4 mg | 4 weeks | 4.00 mL (400 units) | Loading phase 2x/week |
| 2.5 mg | Maintenance | 2.50 mL (250 units) | Maintenance 1x/week |
Available Vial Sizes
2 mg
2 mg vial
5 mg
5 mg vial
10 mg
10 mg vial
Citations
- [1]Thymosin Beta-4: A Multi-Functional Regenerative Peptide (biology review, not a dosing study). Expert Opinion on Biological Therapy, 12(1), 37-51. Link(Reviewed: 2026-02-27)